Q1 EPS Estimates for Aktis Oncology Boosted by HC Wainwright

Aktis Oncology (NASDAQ:AKTS) – Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Aktis Oncology in a research report issued to clients and investors on Tuesday, March 31st. HC Wainwright analyst R. Burns now anticipates that the technology company will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.64). HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.72) EPS and FY2027 earnings at ($2.35) EPS.

Other analysts have also issued research reports about the company. Leerink Partners assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 target price on the stock. JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price target on the stock. Bank of America assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price objective for the company. TD Cowen initiated coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating on the stock. Finally, Wall Street Zen raised Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $32.00.

Aktis Oncology Stock Performance

Shares of Aktis Oncology stock opened at $17.07 on Thursday. Aktis Oncology has a 1-year low of $14.72 and a 1-year high of $29.16. The business’s 50 day moving average is $19.13.

Insider Transactions at Aktis Oncology

In other news, Director Ecor1 Capital, Llc purchased 2,222,222 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were purchased at an average price of $18.00 per share, with a total value of $39,999,996.00. Following the purchase, the director directly owned 4,348,658 shares of the company’s stock, valued at approximately $78,275,844. This represents a 104.50% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Bioventures 2018 L.P. Mpm acquired 1,112,777 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the transaction, the insider owned 10,260,064 shares in the company, valued at $184,681,152. The trade was a 12.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 6,117,776 shares of company stock worth $110,119,968 in the last ninety days. Company insiders own 3.30% of the company’s stock.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.